Press
Releases

Press Releases

June 5, 2024
Altimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Follow-on analyses of non-invasive tests from Phase 1 trials in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) suggest the potential for meaningful histologic improvements with MASH biopsy readouts in Q1 2025 Based on a quantitative systems pharmacology (QSP) computational model,
May 29, 2024
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md. , May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Jefferies Global
May 7, 2024
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md. , May 07, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: JMP Life Sciences
May 1, 2024
Altimmune to Participate at Two Upcoming Conferences
GAITHERSBURG, Md. , May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris , Chief Medical Officer at Altimmune, will present on behalf of the Company at the following two upcoming conferences: BTIG Obesity
April 25, 2024
Altimmune Statement on the Passing of Dr. Stephen Harrison
GAITHERSBURG, Md. , April 25, 2024 (GLOBE NEWSWIRE) -- The Altimmune team would like to express our sorrow and extend our heartfelt condolences to Dr. Stephen Harrison’s family following his tragic and unexpected passing. Dr. Harrison’s countless contributions to advancing needed treatments for
 

Investor Contact

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe